BMS’ Opdivo + Yervoy Receives the CHMP’s Positive Opinion as a 1L Treatment of Metastatic Colorectal Cancer
Shots:
- Based on the P-III (CheckMate -8HW) study, Opdivo + Yervoy received the CHMP’s positive opinion for MSI-H/dMMR unresectable or mCRC in adults
- The P-III study assessed Opdivo (240mg, followed by 480mg, Q4W) + Yervoy (1mg/kg, Q3W, 4 doses) vs Opdivo (240mg, Q2W, 6 doses, followed by 480mg, Q4W) as monotx. or CT (mFOLFOX-6/FOLFIRI with/without bevacizumab/cetuximab) as a 1L treatment of MSI-H/dMMR mCRC patients (n=839)
- The study met its dual 1EPs, showing improved PFS of 79% per BICR. Consistent PFS benefit was seen. OS is being evaluation continues as a 2EP
Ref: BMS | Image: BMS
Related News:- BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
